Close Menu
Home › Personalis, FLX Bio Sign Research Agreement for Use of Universal Cancer Immunogenomics Platform

Personalis, FLX Bio Sign Research Agreement for Use of Universal Cancer Immunogenomics Platform

May 20, 2019
|
staff reporter

NEW YORK (GenomeWeb) – Personalis said today that it has signed a research agreement with FLX Bio to use its universal cancer immunogenomics ImmunoID Next platform to evaluate therapy-related changes in tumors of advanced cancer patients treated with FLX Bio's FLX475 drug.

As part of the collaboration, FLX Bio will apply the Personalis assay in a patient cohort that is part of a Phase I/II clinical trial evaluating FLX475, a CCR4 antagonist, as monotherapy or in combination with pembrolizumab.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Oct
23
Featured Webinar

Single-Cell Methylation Profiling of Pediatric Tumors via a Unique NGS-based Approach

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Oct
24
Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

What's Popular?

In Cancer

  1. Xylonix, BioGemex Ink MOU to Develop Point-of-Care Cancer Immunotherapy-Response Diagnostic

  2. Complex Genetic Testing Errors Emerge Amid Increasing Panel Use, Consumer Access, Case Series Finds

    Premium

  3. GeneCentric Therapeutics to Launch Phase II Validation Study for Head and Neck Cancer Subtyper

    Premium

  4. Mission Bio, Onconova Therapeutics Sign Cancer Therapy Research Partnership

  5. Syapse to Provide Real-World Evidence to FDA Oncology Center of Excellence

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.